

BÖLÜM 12

Vazoaktif ilaçlar

Sinem YALÇIN BAYRAKÇI¹

GİRİŞ

Vazokonstriksiyon yapıp, damar tonusu ve ortalama arter basıncını artıran ajanlara vazopresör ilaçlar denir (1). Kalbin kontraktilitesini arttırarak kardiyak debiyi arttıran ajanlara pozitif inotrop ilaçlar denir. Vazoaktif ajan, damar tonusu ve çapına etki eden, şok durumlarının yönetiminde kullanılan vazopresör ve inotropik aktiviteye sahip çeşitli farmakolojik ilaçları tanımlamak için kullanılan bir terimdir (2).

ETKİ MEKANİZMASI

Vazoaktif maddeler katekolamin veya katekolamin bazlı olmayan maddeler olarak da sınıflandırılabilir. Katekolaminler, kardiyovasküler mekanizmalarını alfa-1 (α_1), beta-1 (β_1), beta-2 (β_2) ve dopaminerjik reseptörlerin agonizmi yoluyla uygulayan geniş bir endojen ve sentetik semptomimetik grubunu kapsar. Katekolamin olmayan ajanlar arasında vazopressin reseptör agonistleri, fosfodiesteraz(PDE) inhibitörleri, kalsiyum duyarlılaştırıcı ajanlar, nitrik oksit inhibe edici ajanlar ve anjiyotensin II (ATII) yer alır (3) (Tablo 1).

Alfa adrenerjik reseptörler

α_1 adrenerjik reseptörler vasküler duvardaki düz kas hücreleri üzerinde ve kalpte miyokard hücrelerinde bulunur. Uyarılması ile vazokonstriksiyon ve neticesinde

¹ Uzm. Dr., Dr. Ersin Arslan Eğitim ve Araştırma Hastanesi, Yoğun Bakım Kliniği, drsinembayrakci@gmail.com

SONUÇ

Vazopresörler, vazokonstriksiyona neden olan ve ortalama arter basıncını yükselten güçlü bir ilaç sınıfıdır. Kritik hastalarda vazopresörlerin ve inotropik ajanların kullanımına ilişkin çeşitli tartışmalar mevcuttur. Çoğu, farklı rejimlerle tedavi edilen benzer hasta popülasyonlarını karşılaştıran büyük ölçekli çalışmaların görece azlığından kaynaklanmaktadır. Başlangıç ajanı seçimi, şokun altında yatan şüpheli etyolojiye dayanmalıdır (örneğin, belirgin hipotansiyon olmaksızın kardiyojenik şok için dobutamin, septik ve kardiyojenik şok için hipotansiyon ile birlikte norepinefrin, anafilaktik şok için epinefrin). Vazopresör ilaçlar kullanılırken hastalar yakın olarak monitörize edilmeli, ilave olarak doku oksijenasyonu parametreleri de izlenmelidir. Tedavide asıl amaç hastanın kan basıncını yükseltmek değil, yeterli doku perfüzyonunu sağlamak olmalıdır.

KAYNAKLAR

1. Manaker s.(2020) Use of vasopressors and inotropes, <https://www.uptodate.com/contents/use-of-vasopressors-and-inotropes> (03.07.2020)
2. Altıntaş ND, İskit Topeli A. Vazoaktif ve inotropik ilaçların doğru kullanımı. Yoğun Bakım Derg. 2006; 6: 179-190
3. Goodman and Gilman's (2011) Pharmacological Basis of Therapeutics Twelfth (ed). New York
4. Williamson AP, Seifen E, Lindemann JP, Kennedy RH. WB4101- and CEC-sensitive positive inotropic actions of phenylephrine in rat cardiac muscle. Am J Physiol. 1994; 266:H2462.
5. Annane D, Ouanes-Besbes L, de Backer D, et al. A global perspective on vasoactive agents in shock. Intensive Care Med. 2018;44(6):833–46.
6. Catt KJ, Mendelsohn FA, Millan MA, et al. The role of angiotensin II receptors in vascular regulation. J Cardiovasc Pharmacol. 1984; 6 Suppl 4:S575.
7. Martin C, Saux P, Eon B, et al. Septic shock: a goal-directed therapy using volume loading, dobutamine and/or norepinephrine. Acta Anaesthesiol Scand. 1990;34:413–417.
8. Schreuder WO, Schneider AJ, Groeneveld ABJ, et al. Effect of dopamine vs norepinephrine on hemodynamics in septic shock. Chest. 1989;95:1282–1288
9. Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med. 1993;19:151–154.
10. Ruokonen E, Takala J, Kari A, et al. Regional blood flow and oxygen transport in septic shock. Crit Care Med. 1993;21:1296–1303.
11. Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med. 1997;23:282–287.
12. Chernow B, Roth BL. Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches. Circ Shock. 1986;18:141–155
13. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004;32:1928–1948

14. Martin C, Viviani X, Leone M, et al. Effect of norepinephrine on the outcome of septic shock. *Crit Care Med.* 2000;28:2758–2765.
15. De Backer D, Creteur J, Silva E, et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? *Crit Care Med.* 2003;31:1659–1667
16. Nguyen HB, Rivers EP, Abrahamian FM, et al; Emergency Department Sepsis Education Program and Strategies to Improve Survival (ED-SEPSIS) Working Group. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. *Ann Emerg Med.* 2006 Jul;48(1):28-54.
17. Hollenberg, S.M.J.C., Vasopressor support in septic shock. *Chest.* 2007. 132(5):1678-1687.
18. Williamson AB, Seifen E, Lindemann JP, Kennedy RH. WB4101- and CEC-sensitive positive inotropic actions of phenylephrine in rat cardiac muscle. *Am J Physiol.* 1994 Jun;266(6 Pt 2):H2462-7.
19. Yamazaki T, Shimada Y, Taenaka N, et al. Circulatory responses to afterloading with phenylephrine in hyperdynamic sepsis. *Crit Care Med.* 1982 Jul;10(7):432-5.
20. Allwood, MJ, Cobbold AF, Ginsburg J. Peripheral vascular effects of noradrenaline, isopropyl-noradrenaline and dopamine. *J British Medical Bulletin.* 1963. 19: 132-136.
21. Givertz, M., et al., Approach to the patient with hypotension and hemodynamic instability. *J Irwin Rippe's Intensive Care Medicine.* 7th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams 2012: 307-317.
22. Kee V.R., Hemodynamic pharmacology of intravenous vasopressors. *J Critical care nurse.* 2003. 23(4):79-82.
23. Hoffman, Basic J.B. and c. pharmacology, Adrenoceptor activating & other sympathomimetic Drugs. *J Basic clinical pharmacology,* 1998: p. 118-135.
24. Morgan P. The role of vasopressors in the management of hypotension induced by spinal and epidural anaesthesia. *Can J Anaesth.* 1994 May;41(5 Pt 1):404-13.
25. Goldberg LI. Dopamine--clinical uses of an endogenous catecholamine. *N Engl J Med.* 1974; 291:707
26. Horwitz D, Fox SM 3D, Goldberg LI. Effects of Dopamine in man. *Circ Res.* 1962; 10:237.
27. Dasta JF, Kirby MG. Pharmacology and therapeutic use of low-dose dopamine. *Pharmacotherapy.* 1986; 6:304.
28. Duke GJ, Briedis JH, Weaver RA. Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? *Crit Care Med.* 1994; 22:1919.
29. Löllgen H, Drexler H. Use of inotropes in the critical care setting. *Crit Care Med.* 1990; 18:S56.
30. Cooper BE., Review and update on inotropes and vasopressors. *J AACN Advanced critical care.* 2008. 19(1): 5-13.
31. Hannemann L, Reinhart K, Grenzer O, et al. Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. *Crit Care Med.* 1995; 23:1962.
32. Levy M.M., Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. *J Intensive care medicine.* 2018. 44(6): 925-928.
33. Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. *Anesthesiology.* 2002;96(3):576-582
34. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med.* 2008;358(9):877-887.
35. Schmittinger CA, Torgersen C, Luckner G, et al. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. *Intensive Care Med.* 2012;38(6):950-958.

36. Polito A, Parisini E, Ricci Z, et al. Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis. *Intensive Care Med.* 2012; 38:9.
37. Torgersen C, Dünser MW, Wenzel V, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. *Intensive Care Med.* 2010; 36:57
38. Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. *Crit Care Med.* 2004; 32:1327.
39. Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. *Crit Care Med.* 2002; 30:1899.
40. Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. *Crit Care Med.* 2002; 30:2548.
41. Dünser MW, Mayr AJ, Tür A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. *Crit Care Med.* 2003; 31:1394.
42. Russell JA. Bench-to-bedside review: vasopressin in the management of septic shock. *Crit Care.* 2011;15(4):226.
43. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med.* 2013;41(2): 580-637.
44. Hollenberg SM. Vasoactive drugs in circulatory shock. *Am J Respir Crit Care Med.* 2011;183(7):847-855
45. Torgersen C, Dunser MW, Wenzel V, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. *Intensive Care Med.* 2010;36(1):57-65.
46. Luckner G, Mayr VD, Jochberger S, et al. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. *Crit Care Med.* 2007;35(10):2280-2285.
47. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. *Circulation.* 2003;107(18):2313-2319.
48. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. *Intensive Care Med.* 2001; 27(8):1416-1421.
49. Tayama E, Ueda T, Shojima T, et al. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. *Interact Cardiovasc Thorac Surg.* 2007;6(6): 715-719
50. Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. *Intensive Care Medicine.* 2006;32(11):1782-1789.
51. Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. *Crit Care.* 2009;13(4):R130.
52. Gordon AC, Wang N, Walley KR, Ashby D, Russell JA. The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. *Chest.* 2012;142(3):593-6
53. Jeon Y, Ryu JH, Lim YJ, et al. Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. *Eur J Cardiothorac Surg.* 2006;29(6):952-956.
54. Yimin H, Xiaoyu L, Yuping H, Weiyan L, Ning L. The effect of vasopressin on the hemodynamics in CABG patients. *J Cardiothorac Surg.* 2013;8:49.
55. Jeon K, Song JU, Chung CR, et al. Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic shock: a prospective randomized trial (DO-VSS). *Crit Care.* 2018; 22:131.

56. Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. *Crit Care Med.* 2002; 30:1899.
57. Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. *Crit Care Med.* 2002; 30:2548.
58. Al-Hesayen A, Azevedo ER, Newton GE, Parker JD. The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure. *J Am Coll Cardiol.* 2002; 39:1269.
59. Löllgen H, Drexler H. Use of inotropes in the critical care setting. *Crit Care Med.* 1990; 18:S56.
60. Antonucci E, Fiaccadori E, Donadello K, et al. Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment. *J Crit Care.* 2014;29:500-11.
61. Tomioka T, Shimada S, Ito Y, et al. Myocardial depression induced by severe sepsis: successful rescue using extracorporeal cardiopulmonary resuscitation from initial phase of severe sepsis. *BMJ Case Rep.* 2015;2015.
62. Zangrillo A, Putzu A, Monaco F, et al. Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials. *J Crit Care.* 2015;30:908-13
63. Zhang Z, Chen K. Vasoactive agents for the treatment of sepsis. *Ann Transl Med.* 2016 Sep;4(17):333.
64. Rauch H, Motsch J, Böttiger BW. Newer approaches to the pharmacological management of heart failure. *Curr Opin Anaesthesiol.* 2006;19:75-81.
65. Sperry JL, Minei JP, Frankel HL. Early use of vasopressors after injury: caution before constriction. *J Trauma.* 2008; 64(1):9-14
66. Vincent JL, De Backer D. Circulatory shock. *N Engl J Med.* 2013;369(18):1726-1734
67. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. *JAMA.* 1994;272(17):1354-1357
68. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) Developed with the special contribution of the heart failure association (HFA) of the ESC. *Eur Heart J.* 2016;37(27):2129-2200
69. van Diepen S, Katz JN, Albert NM et al (2017) Contemporary management of cardiogenic shock: a scientific statement from the American heart association. *Circulation.* 2017;136(16):e232-e268.
70. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for the management of sepsis and septic shock: 2016. *Intensive Care Med.* 2017;43:304-377.
71. National Guideline Centre (UK). Sepsis: Recognition, Assessment and Early Management. London: National Institute for Health and Care Excellence (UK); 2016 Jul. PMID: 27441326.
72. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. *JAMA.* 2016; 316(5):509-518.
73. Vieillard-Baron A, Caille V, Charron C, et al. Actual incidence of global left ventricular hypokinesia in adult septic shock. *Crit Care Med.* 2008;36(6):1701-1706
74. Hollenberg SM. Inotrope and vasopressor therapy of septic shock. *Crit Care Clin.* 2009;25(4):781-802

75. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med.* 2010; 362:779.
76. LeDoux D, Astiz ME, Carpati CM, et al. Effects of perfusion pressure on tissue perfusion in septic shock. *Crit Care Med.* 2000 Aug;28(8):2729-32.
77. Bourgoin A, Leone M, Delmas A, et al. Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. *Crit Care Med.* 2005;33:780–786
78. Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure targets in patients with septic shock. *N Engl J Med.* 2014;370:1583–1593
79. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. *N Engl J Med.* 1994; 330(24):1717–1722
80. Jones AE, Shapiro NI, Trzeciak S, et al. Emergency Medicine Shock Research Network (EMSHOCKNet) Investigators. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. *JAMA.* 2010 Feb 24;303(8):739-46.
81. Jansen TC, van Bommel J, Schoonderbeek FJ, et al. LACTATE study group: early lactate-guided therapy in intensive care unit patients: A multicenter, open-label, randomized controlled trial. *Am J Respir Crit Care Med.* 2010;182:752–761
82. Teboul JL, Saugel B, Cecconi M, et al. Less invasive hemodynamic monitoring in critically ill patients. *Intensive Care Med.* 2016; 42:1350–1359
83. Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring. task force of the European society of intensive care medicine. *Intensive Care Med.* 2014; 40:1795–1815
84. Merouani M, Guignard B, Vincent F, et al. Norepinephrine weaning in septic shock patients by closed loop control based on fuzzy logic. *Crit Care.* 2008;12:R155
85. Hammond DA, McCain K, Painter JT, et al. Discontinuation of vasopressin before norepinephrine in the recovery phase of septic shock. *J Intensive Care Med.* 2017;885066617714209
86. Bissell BD, Magee C, Moran P, et al. Hemodynamic instability secondary to vasopressin withdrawal in septic shock. *J Intensive Care Med.* 2017;34(9):761-765.
87. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. *Lancet.* 2007;370(9588):676–684
88. Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment and mortality of septic shock. *Crit Care Med.* 2009;37(3):811–818
89. Myburgh JA, Higgins A, Jovanovska A, et al. CAT Study investigators. A comparison of epinephrine and norepinephrine in critically ill patients. *Intensive Care Med.* 2008;34(12):2226–2234
90. Annane D, Sébille V, Duboc D, et al. Incidence and prognosis of sustained arrhythmias in critically ill patients. *Am J Respir Crit Care Med.* 1998;178(1):20–25
91. Bohr DF. Adrenergic receptors in coronary arteries. *Ann N Y Acad Sci.* 1967; 139:799-807.
92. Day NP, Phu NH, Bethell DP, et al. The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. *Lancet.* 1996;348:219–223
93. Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience with phenylephrine as a component of the pharmacologic support of septic shock. *Crit Care Med.* 1991; 19:1395.
94. Dalimonte MA, DeGrado JR, Anger KE. Vasoactive Agents for Adult Septic Shock: An Update and Review. *Journal of Pharmacy Practice.* 2020;33(4):523-532.